Rationale: Paracrine secretions seem to mediate therapeutic effects of human CD34 + stem cells locally transplanted in patients with myocardial and critical limb ischemia and in animal models. Earlier, we had discovered that paracrine secretion from human CD34 + cells contains proangiogenic, membrane-bound nanovesicles called exosomes (CD34Exo).
S tem cell-and progenitor cell-based therapies have emerged as one of the most promising treatment options for patients with cardiovascular disease. Transplantation of autologous human CD34 + stem cells has been shown to improve perfusion and function in ischemic tissues and reduce amputation rates in patients with critical limb ischemia. 1, 2 Laboratory experiments suggest that the benefits of human CD34 + cell transplantation occur primarily via increases in vascular angiogenesis. 3 Although involvement of CD34 + cellsecreted paracrine factors in the angiogenic process has been implicated, 4 the specific components and mechanisms by which the paracrine factors induce vessel growth and functional recovery post-ischemia remain largely undefined.
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In our earlier study, we have established a novel mechanism that human CD34 + cells secrete membrane-bound nanovesicles called exosomes (ie, CD34Exo) that mediate most of the proangiogenic paracrine activity of the cells. 5 We have shown that the exosomes secreted by CD34 + cells were similar to exosomes described in previous reports-in their morphology, in size and shape, in expressing known exosomal protein markers and in expressing CD34 + cell-specific CD34 protein maker on their surface. Moreover, CD34Exo mimicked the function of their parent cells, at least in part, and induced angiogenic activity both in vitro and in vivo. Exosomes from several different cell types have been shown to carry and transfer selective cytosolic components such as proteins, lipids, and nucleic acids 6 to communicate with cells at the vicinity or at a distance, altering their function. 7, 8 Interestingly, the unique cargo of exosomes is often distinct from the cell of their origin, although they are also known to carry selective cell-specific signature molecules such as parent cell-specific surface proteins or disease-specific signature proteins originating from the parent cells.
In several recent parallel investigations, role of exosomes as a mediator of cardiac communication among different cell types in the heart has been studied intensively. Both human and mouse stem and progenitor cell-derived exosomes have been shown to augment myocardial function post-ischemia. [9] [10] [11] [12] Remarkably, cardiac progenitor cell-derived exosomes isolated from neonatal patients were found to have higher regenerative potential for cardiac tissue repair compared with cardiac progenitor cell exosomes from older children. 13 Moreover, expression of certain exosomal cargo, such as miR-126, was significantly lower under high-glucose or diabetes mellitus conditions in human CD34 + exosomes, indicating that the exosomal cargo is dependent on the physiological condition of the cell of their origin. Recent research highlights significant potential of exosomes derived from pericardial fluid and plasma obtained from human heart failure patients to induce therapeutic angiogenesis. [14] [15] [16] In contrary to the beneficial effects shown by the stem cell exosomes, cardiac fibroblast-derived exosomes were shown to disseminate the damaging effects of cardiac remodeling by transferring miR-21* as a paracrine signaling mediator of cardiac hypertrophy. 17 Although most of the current cardiovascular exosome studies have examined the RNA and miRNA content and function, the in vivo uptake mechanisms of exosomes and exosomal miRNAs are largely undefined.
In this study, we have investigated the role of CD34Exo in the beneficial angiogenesis associated with CD34 + cell therapy after ischemic injury by (1) exploring whether CD34Exo induce beneficial effects in the absence of cells or other paracrine factors, (2) identifying the molecular components responsible for the angiogenic and therapeutic function of CD34Exo, (3) studying the in vitro and in vivo uptake mechanisms of CD34Exo.
Methods

Cell Culture and Exosome Isolation
CD34
+ cells and the CD34 + -cell-depleted mononuclear cells (MNCs) were obtained from Baxter Healthcare Corporation (Deerfield, IL). The cells were purified from mobilized peripheral blood mononuclear cells (AllCells LLC, Emeryville, CA) with an Isolex 300i device (Baxter Healthcare); cell purity (85% to 95%) was determined via flow cytometry. Both CD34 + cells and MNCs (250 000 cells/ mL) were cultured in X-VIVO 10 serum-free cell culture medium (Lonza, Inc, Allendale, NJ), and ultrapure exosomes were isolated from the conditioned media (CM) by ultracentrifugation and separated from the soluble protein fraction on a sucrose gradient. 5 The exosomes from both cell types were characterized using dynamic light scattering, flow cytometery analysis, electron microscopy, and immunoblotting as described before. 5, 18 Human umbilical vein endothelial cells (HUVECs; Lonza) were maintained in endothelial growth medium-2 (EGM-2; Lonza, Inc) and starved in EBM-2 medium containing 0.25% fetal bovine serum for 24 hours before cell assays were performed. 
Mouse Hindlimb Ischemia Model
Novelty and Significance
What Is Known?
• Human CD34 + stem cells have been shown to induce therapeutic neovascularization in preclinical studies and in phase I, II, and III clinical trials.
• One of the key mechanisms by which CD34 + cells induce neovascularization seems to include paracrine secretion.
• Exosomes, secreted nanovesicles, are one of the major components of CD34 + cell paracrine secretion, which have independent angiogenic activity, both in vitro and in vivo.
What New Information Does This Article Contribute?
• Exosomes from CD34 + cells induce therapeutic angiogenesis that are mediated by exosomal angiomiRs such miR-126-3p.
• CD34 + exosomes are most efficiently internalized by endothelial cells in the ischemic tissue to induce cell cycle induction, angiogenesis, and proliferation.
• Exosome-shuttled angiomiRs may signify amplification of stem cell function and may explain the angiogenic and therapeutic benefits associated with CD34 + stem cell therapy.
In this study, we addressed a key undefined paracrine mechanism by which human CD34 + stem cells mediate their beneficial effects. Our data show that exosomes, a major component of the paracrine secretion from CD34 + cells, stimulate beneficial angiogenesis in a mouse model of hindlimb ischemia. CD34 + exosomes were selectively enriched with several angiomiRs that are distinct from miRs in nontherapeutic exosomes from CD34 − mononuclear cells. Another key discovery is the first evidence of an in vivo trafficking mechanism of CD34 + exosomes and exosome-shuttled angiomiRs. Our findings have both scientific and clinical importance. It will lead to a deeper understanding of the mechanisms of stem cell exosomes trafficking and function on one hand and therapeutic interventions on the other. 
Laser Doppler Perfusion Imaging and Scoring for Limb Functional Recovery
For laser Doppler measurements of the ischemic and control limbs, animals were anesthetized with isoflurane (2%), and laser Doppler perfusion imaging measurements were taken at 7, 14, 21, and 28 days after the hindlimb ischemic surgery. At each time point, tissue perfusion was measured via laser Doppler perfusion imaging, measuring blood flow in both the ischemic and nonischemic limb and reporting results as the ratio of these 2 measurements. Ischemic and nonischemic tissues were harvested at day 28 for histological analyses. Before euthanasia, the mice were injected with 50 µg of BS-1 lectin to identify the mouse vasculature. In addition, motor function and tissue damage was semiquantitatively assessed on postoperative days 7, 14, 21, and 28 by established scoring systems.
Immunohistology for Quantification of Capillary Density
At day 28, muscle tissue from the ischemic limb was harvested, fixed in methanol, paraffin embedded, and cross-sectioned (6 μm) for histological immunostaining. Briefly, sections were blocked with 10% donkey serum (30 minutes; room temperature). Tissue slices were stained with primary antibody (Vector Laboratories, Burlingame, CA) against BS-1 lectin, an endothelial cell marker, for 1 hour at 37°C. AlexaFluor-conjugated secondary antibody (Invitrogen Corporation, Carlsbad, CA) was then added and nuclei were counterstained with DAPI (4′,6-diamidino-2-phenylindole; Vector Laboratories). BS-1 lectin-positive cells were imaged and quantified using fluorescent microscopy (Zeiss).
miRNA Quantification
Total RNA from the CD34 + cells, CD34 + -depleted MNCs, and their respective exosome preparations were extracted using the miRNeasy Mini Kit (Qiagen) according to the manufacturer's protocol (including a DNase step). Taqman small RNA assay and Taqman quantitative real-time polymerase chain reaction (qRT-PCR) were used to assess 
Angiogenic Mechanisms of Human CD34 + Exosomes 1469
miRNA and mRNA expressions, respectively. miRNA and mRNA expressions were normalized to U6 or 18s rRNA, respectively.
miRNA Microarray
miRNA profiling was completed at Asuragen using Affymetrix miRNA microarrays, and data analysis was performed by Asuragen. CD34 + cells, CD34Exosomes, MNCs (depleted of CD34 + cells), and MNCExo-all isolated from the same donor-were processed and compared for 1100 known human miRNAs. At least 3 healthy donors were used for the experiments (n=3). RNA was isolated as before. The expression level signals were scaled in GCOS 1.2 to give a median array intensity of 100. This was done to enable different arrays to be compared. The program Spotfire DecisionSite 8.2 (www.spotfire. com) was used for gene-profiling analysis.
Locked Nucleic Acid-Mediated miRNA Knockdown
Anti-miR 126-3p or scrambled control locked nucleic acid (Ambion, Carlsbad, CA) was transfected into CD34 + cells using Lipofectamine RNAiMAX (Invitrogen Corporation) for 16 hours. Cells were washed 3 times and replated in fresh media to remove any external miRs. Cells were incubated for exosome secretion for 40 hours. Exosomes were isolated using the protocol described before and used in an in vitro Matrigel tube formation assay using HUVECs to evaluate their angiogenic properties. Mouse hindlimb ischemia model was used to compare the therapeutic efficacy of miR-126 knockdown (KD) exosomes with the control scrambled miR exosomes. Proangiogenic mir-126-3p expression in both the cells and exosomes were quantified using Taqman qRT-PCR as described before.
In Vitro Matrigel Tube Formation Assay
HUVECs (2.0×10 4 , serum-starved overnight) were mixed with either PBS (control), or control scrambled CD34Exo or miR 126-3p-KD CD34Exo collected from the CM of 2.0×10 4 CD34 + cells-and seeded into 48-well plates. The plates were previously coated with 150 µL of growth-factor-reduced Matrigel (BD). Tube formation ability of control or exosome-treated HUVECs was examined by phase-contrast microscopy ≈2 to 4 hours later. Each condition in each experiment was assessed at least in duplicates. Tube length was measured as the mean summed length of capillary-like structures (>6 cell long) per well, per high-power field using ImageJ software.
Exosome Treatment and qRT-PCR of the Hindlimb Ischemia Muscle Tissue
Hindlimb ischemia (HLI) was induced in mice as described before and randomized to receive treatments of PBS control or CD34 + exosome-scrambled RNA or CD34 + exosome-anti-miR-126-3p in the ischemic limb, 2 injections of 10 µL each, flanking the ischemic tissue. A small piece of muscle flanking the treatment areas was dissected after certain time points. Total RNA was isolated, and expression of miR-126-3p, mouse pri-126, mouse SPRED1 (sprouty-related, EVH1 domain-containing protein 1), and mouse VEGF (vascular endothelial growth factor) and other mRNAs were determined as described before. 19 
Live Confocal Imaging and Flow Cytometry Analysis of Cy3-Exo-Treated HUVECs and Ischemic Tissue
Cy3 tagged miR or untagged scrambled control (Ambion) was transfected into CD34 + cells using lipofectamine RNAiMAX (Invitrogen Corporation) for 16 hours. Cells were washed 3 times and replated in fresh media to remove any external miRs. Cells were incubated for exosome secretion for ≈24 to 40 hours. Intact exosomes were RNase treated at 37°C for 10 minutes to remove any external or surface-bound Cy3. RNase activity was stopped by RNase inhibitor. Exosomes were washed with excess PBS, pelleted, resuspended in PBS, applied to HUVECs (that were plated on coverslips), and imaged immediately using live confocal microscopy.
For analysis of fluorescent-treated ischemic tissue, the exosomes were isolated from a stable dye (rhodamine-PE)-treated CD34 + cells. Ischemic tissues, treated with CD34Exo, were harvested at different time points and immediately processed for histology or flow cytometry analyses. For flow cytometry analysis, tissues were digested into single-cell suspension using collagenase digestion (0.5 mg/mL; 20 minutes at 37°C). The cells were first stained with a live-dead kit, fixed (with 4% paraformaldehyde), washed, and then stained with a cocktail of primary/secondary antibodies specific for endothelial cells or smooth muscle cells or fibroblasts. The stained cells were analyzed by flow cytometry (BD LSR Fortessa with 6 lasers; 16-color analysis, CA). For immunofluorescence studies, mice were injected with lectin (Vector Laboratories; injected by tail-vein injections), hindlimb tissues were processed immediately after harvesting, stained for lecin, and imaged using Nikon A1R laser scanning confocal microscopy.
Quantified results are presented as mean±SEM; comparisons between groups were evaluated with Student t test or ANOVA, and P<0.05 was considered significant. Detailed methods for all protocols used in the article are provided in the Online Data Supplement.
Results
Cell-Free CD34Exo Enhance Therapeutic Recovery and Vascular Angiogenesis in a Mouse Model of HLI
To evaluate the therapeutic efficacy of CD34Exo, we isolated and purified CD34Exo as described previously. 5 Using dynamic light-scattering analysis, we confirmed that isolated CD34Exo fraction is devoid of contaminating protein aggregates and larger extra cellular vesicles (Online Figure  I) . CD34Exo-depleted CM, MNCExo, or PBS was used as negative control. To study beneficial effects of CD34Exo on tissue repair post-HLI, we created mouse models by ligating femoral artery as described before. 20 We then injected the ischemic limbs with PBS, CD34
+ cells, CD34-CM, CD34Exo, CD34Exo-depleted CM, or MNCExo-all isolated from equal number of cells (treatment dose: 5×10 6 cells/ kg). Mice treated with CD34 + cells, CD34-CM, or CD34Exo had robust improvements in tissue necrosis, tissue perfusion, limb motor function, and limb salvage compared with controls ( Figure 1A through 1E) . Interestingly, we observed that that the ischemic limbs injected with CD34 Exo, but not with MNCExo, were retaining their limbs and overall muscle mass, which were evident as early as day 7 post-HLI/ treatment (Online Table IA and IB). Quantification of limb tissue microcapillary density indicated significant increase in the mice treated with CD34 + cells, CD34Exo, or CD34-CM (Figure 2A and 2B) , suggesting enhanced angiogenesis. Interestingly, CD34-CM depleted of CD34Exo (CD34Exo-depleted-CM) lost its beneficial effects (Figures 1 and 2) , suggesting that the exosomes in CD34-CM provide most, if not all, of the beneficial effects. Together, these data suggest that cell-free CD34Exo have independent therapeutic activity similar to that of CD34 + cells and that CD34Exo induces angiogenesis.
CD34Exo Is Enriched With Proangiogenic miR-126-3p and Loss of miR-126-3p Attenuates CD34Exo-Mediated Angiogenesis
To identify factors responsible for CD34Exo-induced beneficial effects and therapeutic angiogenesis, we examined the exosomal protein and RNA content. Exosomes function as mediators of cell-cell communication by selectively carrying biologically active molecules in the form of proteins and miRNAs. 5 To this end, we extracted protein from CD34Exo and blotted using human angiogenesis protein array that contains known proteins with angiogenesis function (Online Figure II) . Angiogenic protein profiling indicated no significant enrichment of proteins in CD34Exo as compared with MNCExo ( Figure 3A and 3B) . We then isolated RNA from angiogenic CD34Exo and performed microarray profiling of miRNAs comparing that to control nonangiogenic MNCExo. To avoid contaminating RNAs sticking to outside of exosomal membranes, we performed RNase A digestion of intact exosomes without altering the quantity or quality of the isolated RNA (Online Figure III) . Furthermore, analysis of total exosomal RNA confirmed that CD34Exo was mostly enriched with small RNAs and miRNAs as compared with CD34 + cells (Online Figures IV and V) . miRNA microarray analysis revealed that CD34 + cells and CD34Exo had strong similarity in their miRNA composition and had significantly greater expression of several proangiogenic miRNAs (angiomiRs) as compared with MNCs and MNCExo ( Figure 3C ; Online Figure XI) . We determined the most enriched miRNAs in CD34 + cells and MNCs and those in CD34Exo and MNCExo (Online Table II ). Interestingly, the exosomes from both cell types were distinctively enriched with certain miRNA species of unknown function compared with the cells and vice versa (Online Figure XII and Table II ). The exosome-specific miRNAs may suggest selective packaging of exosomal miRNAs that may be involved in exosome-specific signaling and function in target cells.
MiR-126-3p was one of the most enriched miRNAs in both CD34 + cells and CD34Exo and was one of the most differentially expressed miRNA between CD34 + cells/CD34Exo and MNCs/MNCExo ( Figure 3C ). Further, it was significantly enriched in CD34Exo compared with CD34 + cells ( Figure  4A ). Interestingly, expression of miR-126-3p was lower in CD34Exo from chronic myocardial infarction patient-derived CD34 + cells compared with CD34Exo from healthy individuals, although the difference was not statistically significant (Online Figure XIII) . To address whether miR-126-3p contributes to CD34Exo function, we knockdown (KD) its expression in CD34 + cells using anti-miR-126-3p or a scrambled miR control; the exosomes isolated from miR-126KD cells had reduced expression of miR-126-3p (miR-126-KD-Exo) compared with the exosomes isolated from scrambled controltreated cells (scrambled-control-Exo; 99% decrease; Figure  4A ). To measure the angiogenic activity of miR-126-KD-Exo, we treated HUVECs with either miR-126-KD-Exo or scrambled-control-Exo and quantified the tube length in an in vitro Matrigel tube formation assay. We observed a significant decrease in tube length in miR-126-KD-Exo-treated HUVECs compared with scrambled-control-Exo-treated HUVECs ( Figure 4B ; Online Figure IX) . These results indicate that angiomiR-126-3p present in CD34Exo is a potential mediator of CD34Exo-mediated angiogenic function in vitro.
CD34Exo Directly Transfers miR-126-3p to Regulate Gene Expression in Ischemic Hindlimb Tissue
To gain further mechanistic insights into the role of exosomal miR-126-3p in CD34Exo-induced therapeutic angiogenesis, we injected mouse ischemic hindlimb with either miR-126-KD-Exo or scrambled-control-Exo and measured limb function and capillary density ( Figure 4C ). miR-126-KDExo-treated ischemic hindlimbs had significantly lower limb perfusion, limb motor function, and limb salvage compared with the scrambled-control-Exo ( Figure 4D through 4G) . Similarly, the capillary density as measured by lectin-positive cells was significantly lower in the miR-126-KD-Exo-treated ischemic hindlimbs ( Figure 4H and 4I ). This indicates that knocking down of exosomal miR-126-3p abrogated the angiogenic and therapeutic potential of CD34Exo.
Next, to investigate whether the observed angiogenesis was mediated directly by the transfer via CD34Exo or indirectly as a result of de novo synthesis in the mouse ischemic tissue, we quantified mature miR-126-3p (Exo-transferred plus mouse tissue synthesized) and mouse-specific primary miR-126-3p (pri-miR-126; only mouse tissue synthesized) in the ischemic limbs treated with PBS, miR-126-KD-Exo, or scrambled-control-Exo. We detected significantly high level of miR-126-3p in the scrambled-control-Exo-treated limbs compared with miR-126-KD-Exo-treated limbs ( Figure  5A ). On the contrary, there was no difference in the levels of mouse-specific pri-miR-126 levels between hindlimbs treated with PBS, scrambled-control-Exo, or miR-126-KD-Exo ( Figure 5B ), suggesting that there was no de novo synthesis of miR-126-3p in the mouse limb post-CD34Exo treatment. Therefore, the observed increase in mature miR-126-3p postCD34Exo treatment was most likely because of the direct transfer of mature miR-126-3p from the cargo of CD34Exo.
We then tested whether CD34Exo-mediated enhanced angiogenic activity could be because of the regulation of known miR-126-3p target mRNAs in mouse hindlimbs. In line with this hypothesis, we observed a significant reduction in SPRED1 mRNA expression, a direct target of miR-126-3p, 19, 21 in scrambled-miR-CD34Exo, but not in miR-126-KD-Exotreated HLI tissues compared with other treatment groups ( Figure 5C ). Conversely, we observed increased expression of proangiogenic mRNAs including VEGF, ANG1 (angiopoietin 1), and MMP9 (matrix metallopeptidase 9) by several folds in the scrambled-control-Exo-treated HLI tissues ( Figure 5D through 5F). Similar gene expression pattern was observed for additional genes involved in angiogenic pathways (Online Figure X) . Notably, miR-126-KD-Exo treatment failed to induce angiogenic mRNA expression compared with PBS treatment in these ischemic hindlimbs. Collectively, these data suggest that CD34Exo directly delivers miR-126-3p to ischemic tissues by inducing angiogenic gene expression. and mouse pri-miRNA (B) normalized to U6; mSPRED1 (sprouty-related, EVH1 domain-containing protein 1; C), mVEGF (vascular endothelial growth factor; D), ANG1 (angiopoietin 1; E), and MMP9 (matrix metallopeptidase 9; F) mRNAs normalized to 18s RNA, in tissue homogenates of nonischemic (NI) or ischemic (I) limbs treated as indicated, at 4 h; n=4 to 9; *P<0.05 vs PBS or PBS I and †P<0.05 vs scrambled-control-Exo.
Uptake and Transfer of CD34Exo and Its miRNA Content In Vitro and In Vivo
To investigate the direct transfer of miRNAs via CD34Exo, we used fluorescently (Cy3)-tagged miRNA and isolated exosomes containing Cy3-miR. We treated CD34 + cells with Cy3-miR and isolated Cy3-miR-containing exosomes from the CM of those cells. We eliminated nonspecific exosomal surface-bound Cy3-miR by treating the isolated CD34Exo with RNase A. Flow cytometry analysis confirmed that Cy3-miR is contained in CD34Exo (Figure 6A and 6B) . 22 Next, we treated HUVECs with Cy3-miR-CD34Exo or with a nonfluorescent control-miRNA-CD34Exo prepared in the same way. Live confocal microscopic imaging shows presence of Cy3-positive punctate cytosolic vesicles only in the Cy3-miR-CD34Exo-treated HUVECs but not in the controls ( Figure 6C ). To study the in vivo uptake of CD34Exo in the ischemic hindlimb, we used PE-CD34Exo isolated from the CM of rhodamine-PE-tagged CD34 + cells and treated PE-CD34Exo or an unstained Exo control to the ischemic hindlimb, digested the tissue to prepare single cell suspensions, and analyzed for the presence of PE fluorescence in the cells using flow cytometry (at 2 hours) and histology at 12 hours (Online Figure XI) . To identify the individual cell types uptaking CD34Exo, we used known cell type-specific antibodies. Our data revealed that PE-CD34Exo were uptaken most efficiently by endothelial cells as compared with smooth muscle cells and fibroblasts ( Figure 6D and 6E). Interestingly, we observed the appearance of division in PE-CD34Exo-uptaken lectin-positive endothelial cells in the ischemic hindlimb ( Figure 7A ). In this line, CD34Exo-positive endothelial cells displayed different scatter properties than control PBS-uptaken endothelial cells ( Figure  7B ), suggesting that CD34Exo possibly induced cell cycle changes in those cells. To confirm involvement of cell cycle regulators in CD34Exo-injected tissue, we tested the expression of Cyclin genes at day 28 post-CD34Exo injection in the ischemic limbs. We identified increased Cyclin A and Cyclin B mRNA expressions in hindlimbs treated with CD34Exo as compared with PBS control (Figure 7C and 7D ; Online Figure XII ). Collectively, our data suggest that CD34Exo from human CD34 + progenitor cells carry and transfer stable and functional miR-126-3p to activate angiogenic and cell cycle-related gene expression in the mouse ischemic hindlimb tissue (Figure 8 ). 
Discussion
The molecular underpinning of paracrine factor-induced neovascularization that contributes to the therapeutic benefits of human CD34 + cell therapy after tissue ischemia is largely unknown. Here, we demonstrate for the first time that CD34Exo constitutes a key component of the paracrine secretion from CD34 + cells that promotes ischemic tissue repair. Cell-free CD34Exo were independently therapeutic and improved microcirculation in the ischemic limb, similar to CD34 + cells in a mouse model of HLI. Our results provide further insights into the molecular mechanisms underlying the angiogenic activity of CD34Exo by demonstrating that angiomiRs such as miR-126-3p, which are enriched in CD34Exo, have a profound effect on their angiogenic activity. The distinct combination of angiomiRs enriched in CD34Exo may provide a plausible explanation for their superior angiogenic and therapeutic efficacy compared with MNCExo, which is also consistent with enhanced potency of CD34 + cells versus MNCs. 3 MiR-126, known as an essential component of endothelial angiogenic activity, 19 was functional, and it was one of the most enriched miRNAs transported by CD34Exo. Treatment with CD34Exo suppressed endogenous SPRED1, one of the known direct targets of miR-126-3p, and induced expression of several proangiogenic mRNAs, which are not known to be a direct target of miR-126-3p (Online Figure XIII) , in a miR-126-dependent manner. We speculate that additional pathways may play a role in the CD34Exo-mediated angiogenesis. Moreover, the lack of angiogenic activity of miR-126-KD-Exo could also be because of alteration of other unknown moieties (in addition to loss of miR-126-3p) in CD34Exo generated from miR-126-KD-CD34 cells. Thus, miR-126-3p may affect tissue angiogenesis via its direct targets or indirectly by modulating other angiogenic components in exosomes or in the exosome-treated limbs. We do not rule out contribution from other miRNAs or factors in the repertoire of CD34Exo, alone or in combination, to the angiogenic and therapeutic activity of CD34Exo. In agreement, miR-10a and miR-130, enriched in CD34Exo, have antifibrotic activity suggesting that the overall benefits of CD34 + exosomes may exceed beyond angiogenesis. Moreover, our previous work has shown that exosomes from sonic hedgehog-modified CD34 + cells activated angiogenic sonic hedgehog signaling in other cell types. 23 The complete molecular content of CD34Exo and the mechanism of their cell-specific uptake still remains to be fully characterized in future studies.
In patients with coronary artery disease, the plasma levels of miR-126-3p is significantly reduced, 24, 25 indicating a dysfunctional endothelium in those patients. In patients with acute coronary syndrome, miR-126-3p is downregulated across the coronary circulation, implicating a high level of consumption of miR-126-3p in transcoronary passage of patients. 26 These data suggest an essential role of miR-126-3p in regeneration and repair of ischemic tissues. Therefore, CD34Exo-mediated delivery of miR-126-3p or other angiomiRs to the damaged tissues may provide a promising therapeutic strategy 27 as miRNAs are likely to be more stable within the exosome membrane and uptaken efficiently to target cells. 6 Moreover, miRNAs directly supplied in the systemic circulation or injected into the tissues are prone to RNAse digestion and, therefore, are less stable in vivo. Although exosomes are known to play a role in angiogenesis during cancer metastasis, 28 in immune regulation, or in disease pathogenesis, 6 their contribution to vessel growth under ischemic cardiovascular conditions is largely unknown. Our findings have unveiled a unique mechanism of revascularization that highlights the contribution of horizontal transfer of angiomiRs from human CD34 + stem cells to endothelial cells that mediate cell-cell communication. Exosome-shuttled angiomiRs may signify efficient amplification of stem cell function and may explain the results of clinical trials demonstrating significant functional improvement from a modest number of transplanted CD34 + cells that are retained in the ischemic tissues. Moreover, we are beginning to propose CD34Exo therapy as a suitable cell-free alternative to CD34 + cell therapy. Exosomes have great potential to overcome certain limitations of cell therapies for cardiovascular diseases, such as retention, viability, and functional impairment of transplanted cells in the unfavorable ischemic environment, while retaining the benefits.
Recent cell therapy approaches have shown promising results to augment cardiac function and quality of life by several means including reduced fibrosis, enhanced vascular angiogenesis, replacement, and repair of damaged myocardial tissue. 1, [29] [30] [31] [32] Emerging evidence highlight a significant contribution from several different stem cell types conferred by paracrine mechanism mediated through exosomes and their miRNA repertoire. 10, 15, [33] [34] [35] [36] [37] [38] Our results identified CD34Exo as a key therapeutic component in the paracrine secretion of human CD34 + stem cells. We have demonstrated a novel mechanism by which cell-free CD34Exo mediates ischemic tissue repair via beneficial angiogenesis. Thus, the benefits of CD34 cell therapy on functional recovery could be induced primarily through CD34Exo-mediated transfer of angiomiRs such as miR-126-3p to endothelial cells in the ischemic tissue. This new knowledge can be used to refine existing treatments and to develop alternative therapeutic approaches that may benefit patients with cardiovascular diseases.
